3BFuture Health Fund

VCMatch tracks 3BFuture Health Fund as an investor focused on Biotech, Pharma, and Medtech companies, Pre-Seed and Seed rounds, United States, Europe, and Israel markets, and $12m check sizes. Upload your deck to compare your startup against the full private matching profile.

Check Size

$12m

Stages

Pre-Seed, Seed, Series A, Series B

Focus Areas

Biotech, Pharma, Medtech

Geography

United States, Europe, and Israel

Investment Thesis

3B Future Health Fund (formerly Helsinn Investment Fund) is a science-first, patient-driven healthcare investor that targets early-stage companies developing transformative therapeutics. The Fund focuses on building a diversified portfolio (10–15 companies) of start-ups in 100% healthcare, with typical initial investments at Series A (and occasionally earlier), reserve capital for follow-ons, and check sizes up to $12 million per company. They prioritise “first-in-class” assets and “First Class Science & Technology,” require preclinical proof-of-concept and strong IP/freedom-to-operate, and actively create value through board participation and hands-on operational, regulatory and business-development support. Time horizon is multi-year (typical holding 5–8 years within a 10-year fund life) with a preference for M&A as the primary exit route.

Is 3BFuture Health Fund right for your startup?

Upload your pitch deck to compare your startup against VCMatch's private investor profile, including fit, timing, and next-step signals.

See If You're a Match View Sample Match

Investment Focus

Who should take a closer look

3BFuture Health Fund is most relevant for founders raising Pre-Seed, Seed, and Series A rounds in Biotech, Pharma, Medtech, and Other, especially across United States, Europe, and Israel, with public check-size signals around $12m.

Focus statement

The Fund is dedicated to early-stage investments in oncology and rare diseases (priority therapeutic areas) across the US, Europe and Israel, seeking technologies that can "progress from the lab to the clinic and create a meaningful impact on patients’ lives."

Value Add

Backed and guided by the Helsinn Group with >40 years of R&D and commercial experience in cancer care (provides industry credibility and strategic resources).
Experienced, senior team with deep drug discovery, R&D, manufacturing, BD/licensing and fund management expertise (team "with over 40 years of experience").
Active ownership model: the Fund "maximise[s] value creation through active participation as shareholders and board members of our portfolio companies."
Access to external senior industry experts across discovery, clinical development, CMC and regulatory affairs, and links to leading institutions and universities.
Science-first screening (requires preclinical proof-of-concept, solid science/technology, IP protection, and a "clean regulatory and approval path").
Portfolio and capital construct: concentrated portfolio (10–15 companies), up to $12M per company, reserved follow-on capital and board seats desirable.
Clear commercial/exit orientation: explicit belief that "M&A will continue to be the prevalent exit route in the biotech space."